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LowUsefulness of PotassiumMonitoring AmongHealthy
YoungWomen Taking Spironolactone for Acne
Molly Plovanich, MD; Qing YuWeng, BS; ArashMostaghimi, MD, MPA
S pironolactone is an androgen receptor antagonist that isan effective treatment for hormonallymediated acne.1-4Although generallywell tolerated, spironolactoneuse is
associated with hyperkalemia among patients with heart fail-
ure taking additional drugs that interfere with potassium
excretion.5 However, the prevalence of spironolactone-
induced hyperkalemia among young women taking
spironolactone for acne is unclear. To date, there have been
4 small-scale clinical studies,6-9 each fewer than 100 patients,
that havemeasured serumpotassiumas a secondary outcome
in patients taking spironolactone for acne. Three studies6-8
yielded zero cases of hyperkalemia, and one study9 showed a
13.7% rate of mild hyperkalemia, which was defined as a se-
rum potassium measurement of 4.8 to 5.3 mEq/L (to convert
potassium level tomillimoles per liter, multiply by 1.0).
Although the US Food and Drug Administration recom-
mends frequent potassiummonitoring in patients taking spi-
ronolactone, it is unclear whether this guideline is applicable
to healthy patients taking spironolactone for acne. If the rate
of hyperkalemia in this population is low and clinically insig-
nificant, the cost of regular potassium monitoring may ex-
ceed the benefit of capturing these cases. In addition, con-
cerns over hyperkalemia and frequent laboratory testingmay
contribute to health care spending and discourage the use of
this effective drug. The objective of this retrospective study
was tomeasure the rate of hyperkalemia in a large population
IMPORTANCE Spironolactone has been shown to be an effective treatment option for
hormonally mediated acne but can cause hyperkalemia. The prevalence of hyperkalemia
among healthy young women taking spironolactone for acne is unclear.
OBJECTIVE Tomeasure the rate of hyperkalemia in healthy young women taking
spironolactone for acne or for an endocrine disorder with associated acne.
DESIGN, SETTING, AND PARTICIPANTS Retrospective study of healthy youngwomen taking
spironolactone for acne. Data from December 1, 2000, throughMarch 31, 2014, were
obtained from a clinical data repository. Outpatient data were collected from 2 tertiary care
centers in the United States. We analyzed rates of hyperkalemia in 974 healthy young women
taking spironolactone for acne. We also analyzed 1165 healthy young women taking and not
taking spironolactone to obtain a profile for the baseline rate of hyperkalemia in this
population. Exclusion criteria were cardiovascular disease, renal failure, and the use of
medications that affect the renin-angiotensin-aldosterone system.
MAIN OUTCOMES ANDMEASURES The rate of hyperkalemia in healthy youngwomen taking
spironolactone for acne was calculated. Secondary measures included spironolactone
prescriber profiles and potassiummonitoring practices.
RESULTS There were 13 abnormal serum potassiummeasurements in 1802measurements
obtained among young women receiving spironolactone therapy, yielding a hyperkalemia
rate of 0.72%, equivalent to the 0.76% baseline rate of hyperkalemia in this population.
Repeat testing in 6 of 13 patients demonstrated normal values, suggesting that these
measurements may have been erroneous. In the remaining 7 patients, no action was taken.
CONCLUSIONS AND RELEVANCE The rate of hyperkalemia in healthy youngwomen taking
spironolactone for acne is equivalent to the baseline rate of hyperkalemia in this population.
Routine potassiummonitoring is unnecessary for healthy women taking spironolactone
for acne.
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of healthyyoungwomen taking spironolactone for acneor for
an endocrine disorder with associated acne to determine
whether potassium monitoring is clinically indicated in this
population.10
Methods
Allmedical records fromDecember 1, 2000, throughMarch31,
2014, at Brigham and Women’s Hospital and Massachusetts
General Hospital (Boston) were evaluated using the Research
Patient Data Repository, a clinical data registry that captures
comprehensive information about patients seen within the
Partners HealthCare system in Boston. Data in the repository
includeclinic visits, inpatient admissions, laboratorydata, op-
erative notes, and pathology reports.
Our search parameters identified patients who were
female, 18 to 45 years old, diagnosed as having acne, given a
prescription for spironolactone, and seen in an outpatient
setting at Brigham and Women’s Hospital or Massachusetts
General Hospital. We excluded patients who had a history of
heart failure, were using medications that affect the renin-
angiotensin-aldosterone system (angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers,
β-blockers, amiloride hydrochloride, or triamterene), or had
nephritis, nephrotic syndrome, renal failure, or chronic
renal disease as defined by a glomerular filtration rate of
less than 60 mL/min.
Each identified medical record was individually re-
viewed (byM.P. and Q.Y.W.) to confirm that inclusion criteria
weremet and to determine the primary clinical indication for
spironolactone therapy, whether the serum potassium mea-
surement was checked after the initiation of spironolactone,
the total number of times the serum potassium measure-
mentwas checked, what specialty prescribed spironolactone
(dermatology vs other), and the age at which the patient be-
gan spironolactone therapy. We collected all serum potas-
sium data available in this cohort, including values obtained
when taking and not taking spironolactone.
Thenormal rangeof serumpotassiummeasurementswas
defined as 3.5 to 5.0 mEq/L, which is the standard reference
range for the institutions at which this study was conducted.
Hyperkalemia was classified as mild (5.1-6.0 mEq/L), moder-
ate (6.1-6.9mEq/L), or severe (≥7.0mEq/L).11,12 All study pro-
tocols were reviewed and approved by the Partners Health-
CareHumanResearch Committee. Informed consentwas not
required.All dataanalysiswasperformedusing statistical soft-
ware (SAS, version 9.4; SAS Institute Inc).
Results
Cohort Selection
The initial Research Patient Data Repository query identified
1559patients, 394ofwhomworkedwithin thePartnersHealth-
Care systemandwere excluded topreserve confidentiality.Of
the remaining 1165, an additional 191 patients were excluded
because of inability to validate that they had taken spirono-
lactone for acne or for an endocrine disorder with associated
acne (Figure 1). Of the remaining 974 patients who had a di-
agnosis of acne and had been prescribed spironolactone, 676
were takingspironolactone foraprimarydiagnosisofacne,and
298were taking spironolactone for anendocrinedisorderwith
acne as a secondary feature. Common endocrine disorders
encountered include polycystic ovary syndrome, hirsutism,
alopecia, and hyperandrogenism.
Practice of PotassiumMonitoring
Weevaluated the currentpracticeofpotassiummonitoring for
patientswithanewprescriptionforspironolactone (Table).The
serum potassiummeasurement was checked in 56.4% of pa-
tients with acne as a primary diagnosis. In contrast, the se-
rum potassium measurement was checked in 74.9% of pa-
tientswithanendocrinedisorderwhohadacneas a secondary
feature (P < .01).
There was substantial variation in how often serum
potassium was measured in patients whose potassium was
monitored, with a range of 1 to 22 tests (mean, 3 tests). In
patients with a sole diagnosis of acne, the mean (SD) num-
ber of serum potassium measurements per person was 2.54
(2.71), with a 95% CI of 2.26 to 2.81. In patients with acne as
a secondary diagnosis, the mean (SD) number of serum
potassium measurements per person was 3.96 (3.78), with a
95% CI of 3.46 to 3.96.
Figure 1. Flowchart of Cohort Selection
1559 Patients 394 Excluded Partners 
HealthCare employees
191 Excluded owing to 
unclear indication, 
other indication, never 
took medication, or 
discontinued use of 
medication in <2 wks
1165 Patients
974 Patients
676 Acne primary 
diagnosis
298 Acne secondary 
diagnosis
In total, 1559 patients were initially identified through the Research Patient Data
Repository query. Of these, 974 whowere prescribed spironolactone for acne
or for an endocrine disorder with associated acne were included in the analysis.
Table. Patient Demographics
Variable
Acne Primary
Diagnosis
(n = 676)
Acne Secondary
Diagnosis
(n = 298)
P
Value
Patients with serum potassium
measurement, %
56.4 74.9 <.001
No. of serum potassium
measurements per patient,
mean (SD)
2.54 (2.71) 3.96 (3.78) <.001
Age, mean (SD), y 27.5 (6.4) 26.2 (6.0) .01
Prescriber, %
Dermatologist 79.3 20.8
<.001Other 6.4 53.0
Unclear 14.3 26.2
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Dermatologists were the overwhelming majority of pre-
scribers for patients with acne as a primary diagnosis. In this
cohort, 79.3% of prescribers were dermatologists, 6.4% were
trained in other fields, and 14.3%were prescribers who could
not be definitively identified. In contrast, in patients with an
endocrine disorder, only 20.8% of prescribers were derma-
tologists, and 53.0%were from other specialties, particularly
endocrine andprimary care. In this cohort, 26.2%of prescrib-
ers could not be definitively identified.
Incidence of Hyperkalemia
In total, 1802 serum potassium measurements were
obtained when patients were taking spironolactone for acne
or for an endocrine disorder with associated acne. Of these,
13 measurements were between 5.1 and 6.0 mEq/L, indicat-
ing a 0.72% rate of mild hyperkalemia (Figure 2). In 6
patients, the elevated values prompted successive testing
within 1 to 3 weeks, revealing normal values in all cases,
suggesting that the original measurements may have been
erroneous. Spironolactone therapy was not discontinued for
any of the patients in the interim. Of the remaining 7
patients, successive testing was not pursued. None of the
patients received additional monitoring such as electrocar-
diography for adverse events related to hyperkalemia. All
patients with hyperkalemia were asymptomatic, and there
were no reported adverse clinical events.
To determine the baseline rate of hyperkalemia in our
population, we calculated the rate of hyperkalemia using all
serumpotassiummeasurements available tous, includingval-
ues obtainedwhen taking andnot taking spironolactone. This
yielded a rate of 0.76% (32 of 4209), which is comparable to
the 0.72% (13 of 1802) rate of hyperkalemia in patients taking
spironolactone.
Discussion
Before this study, the rate of hyperkalemia in healthy young
women receiving spironolactone for acne was unknown. We
identified a low rate of mild hyperkalemia in patients taking
spironolactone for acne that was similar to the baseline rate
of hyperkalemia in this population, suggesting that spirono-
lactone does not significantly alter the rate of clinical hyper-
kalemia in our population.
When a subset of 13 patients with elevated serum potas-
sium measurements underwent repeat testing, all values
were within normal limits, suggesting that the original mea-
surements were erroneous or that the mild hyperkalemia
was transient and quickly self-resolved. In either case, there
were no adverse clinical events, indicating that any mild
hyperkalemia was clinically insignificant. Patients with
acne as a secondary diagnosis did not have higher rates
of hyperkalemia, despite their underlying endocrine
disorder.
For the first time todate,wealso report anestimateofhow
frequently the serum potassiummeasurement is checked by
physicians in clinical practice. Dermatologists had the lowest
ratesofpotassiummonitoring,whereas internalmedicinesub-
specialties, whose patient panel was enriched with endo-
crine disorders, hadhigher rates. It is unclearwhether this ef-
fect is influenced by the patients’ comorbidities or reflects
easier access to laboratory monitoring.
What are the implications of our results for clinical prac-
tice? Given our inability to identify any instances of persis-
tentandclinicallymeaningfulhyperkalemia in 14yearsof clini-
cal data, we suggest that potassium monitoring should no
longer be conducted inhealthy youngwomen taking spirono-
lactone for acne. Abandoning frequent potassium monitor-
ing can decrease unnecessary office visits and reduce health
care spending.
Spironolactone is an inexpensive, generic drug, with a
monthly cost of $4.00 when obtained through major retail-
ers in the United States.13-15 The cost of a single serum
potassium measurement is $6.27 as determined by the 2014
clinical laboratory fee schedule by the Centers for Medicare
& Medicaid Services.16 However, a serum electrolyte panel
costing $43.51 is frequently ordered in conjunction with the
potassium measurement. Within our study population, the
latter panel equates to up to $78 405.02 in spending that
does not appear to yield clinically significant information
for the studied population. Furthermore, these estimates do
not take into account patient-specific costs such as time and
lost work productivity. It is likely that patients and physi-
cians have restricted the use of spironolactone because of
concerns regarding hyperkalemia and the feasibility of the
recommended potassium monitoring frequency. The ability
to prescribe spironolactone safely without drug monitoring
will allow for expanded use of this inexpensive and effica-
cious drug for young women with acne.
Our results are limited by the fact that the study
was performed at just 2 hospitals, which may reflect only a
subset of national prescribing patterns. Although the retro-
spective nature provides insight into how frequently pre-
scribers check serum potassium measurements, a substan-
tial subset of patients did not have their potassium level
checked, and potential cases of hyperkalemia may not have
been captured. A small percentage of patients were being
prescribed spironolactone by physicians from an outside
Figure 2. Hyperkalemia Cases
Rechecked 7No action taken
Normal
1802 Serum potassium measurements
when taking spironolactone
13 Measurements >5.0 mEq/L
2 Measurements >5.5 mEq/L
6
Of 1802 serum potassiummeasurements for 974 patients taking
spironolactone for acne, 13 exceeded 5.0mEq/L. This corresponds to a 0.72%
rate of mild hyperkalemia, which is equivalent to the baseline rate of
hyperkalemia in this population. To convert serum potassium level to millimoles
per liter, multiply by 1.0.
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hospital or clinic, from which we could not capture
potassium data. This could have resulted in falsely low esti-
mates of how often physicians check serum potassium
measurements.
Moving forward, it will be important to educate mul-
tiple specialties about our results and their implications for
clinical practice. In addition, it will be necessary to replicate
our results in similar populations at other institutions.
Conclusions
Inconclusion,our results suggest that routinepotassiummoni-
toring is unnecessary for healthy young women taking spi-
ronolactone for acne. The low rate of hyperkalemia may en-
couragemore health care professionals to consider the use of
this highly effective drug in their clinical practice.
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